FINWIRES · TerminalLIVE
FINWIRES

受需求疲软影响,Avista第一季度各业务板块能源销量均出现下滑

By

-- Avista (AVA) 周二公布了第一季度财报。受温和天气影响,电力和天然气需求下降,其中居民用电量下降 10%,商业用电量下降 6%。 该公司报告称,其运营部门 Avista Utilities 的居民用电总量为 1.15 吉瓦时,低于去年同期的 1.27 吉瓦时。 截至 3 月 31 日的第一季度,商业用电量为 768 兆瓦时,低于去年同期的 808 兆瓦时。 该公司报告称,第一季度工业用电量为 455 兆瓦时,低于去年同期的 469 兆瓦时;批发用电量为 912 兆瓦时,低于去年同期的 951 兆瓦时。 该公司报告称,其运营部门 Avista Utilities 的住宅天然气总销量为 84907 亿英热单位(Btu),低于去年同期的 98881 亿英热单位。 截至 3 月 31 日的季度,商业天然气销量为 51161 亿英热单位,低于去年同期的 59619 亿英热单位。 该公司报告称,第一季度天然气批发量为 54461 亿英热单位,低于去年同期的 67528 亿英热单位。 其他天然气销量为 54461 亿英热单位,低于去年同期的 54019 亿英热单位。 Avista 还在推进一项新的企业资源规划系统,该系统计划于 2028 年完成,预计资本支出约为 1.3 亿美元,旨在提高运营效率和财务报告能力。

Price: $40.81, Change: $+0.25, Percent Change: +0.62%

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Posco Holdings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to USD94 from USD70, valuing POSCO at 0.66x 2026 P/BV, above its three-year mean of 0.52x. Our neutral view reflects: (i) recovering steel fundamentals supported by China's 2025 crude steel output declining 4.4% Y/Y and South Korea's anti-dumping duties on Chinese steel, which provides a pricing moat for Posco; and (ii) lithium market recovery with prices surging 49% YTD through April, supporting POSCO's battery materials segment which narrowed Q1 2026 losses significantly. POSCO's Australian and Argentine lithium acquisitions bolster its battery materials growth strategy. Additionally, the new Mid-term Shareholder Return Policy (2026-2028) targeting a 35%-40% payout ratio demonstrates commitment to shareholder value. However, risks include an aggressive 61% capex increase to KRW11.3 trillion in 2026, execution challenges on international projects, and persistent margin pressures. We adjust our 2026 EPS estimate to KRW6,379 from KRW5,932 and 2027 to KRW8,036 from KRW7,820.

$PKX
Research

Propel Holdings Maintained at Buy at Stifel Canada After Q1 Results; Price Target Kept at C$32.00

Stifel Canada on Tuesday reiterated its buy rating on the shares of Propel Holdings (PRL.TO) and its C$32.00 price target following the company's first-quarter results."Propel reported an upside FQ1, underscoring strength in loan growth alongside stable credit performance, on the back of the rebound in credit quality and subsequent new origination activity we saw exiting last quarter. Importantly, credit metrics PCLs and net-charge-offs normalized this quarter, supporting a recovery in ROE and fueling yet another bump in Propel's quarterly dividend (11th consecutive raise at +6.7% to $0.24/share). Net/net - results further reinforce resilience in the non-prime consumer backdrop, in-line with recent prints from US consumer credit peers. FY guide is being maintained, reaffirming the growth trajectory ahead, while suggesting some conservatism amidst the current macro uncertainty. Conference call tomorrow at 8:30am ET (dial-in: 1-888-699-1199/webcast). Our key focus on the call will be around (1) outlook for US consumer credit quality, (2) growth outlook for LaaS, (3) pace/scale of ongoing growth investments to support US expansion/Propel Bank launch," analyst Suthan Sukumar wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $24.15, Change: $+2.25, Percent Change: +10.27%

$PRL.TO
Australia

Correction: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts polled by FactSet expect 2.22 billion euros.BioNTech shares were down nearly 4.4% in Tuesday premarket activity.Price: $96.56, Change: $-2.79, Percent Change: -2.81%

$BNTX